Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized study of ipilimumab + nivolumab with immunogenic chemotherapy in luminal B metastatic breast cancer
2017-000220-10Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Aug 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab, nivolumab, pegylated liposomal doxorubicin and cyclophosphamide in breast cancer and Luminal B breast cancer (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Toxicity assessment. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
breast cancerLuminal B breast cancer
Beyond the preview
Go deeper on 2017-000220-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000220-10.